Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024045 · ClinicalTrials.gov registry record · Phase 1
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
A Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 316
- Enrollment target
- 20
- Study locations
NCT05024045: Active Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Eli Lilly and Company.
NCT05024045 is a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 316 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05024045, a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 316 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Primary Outcome
Measured by the number of patients with dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Pirtobrutinib
- DRUG LOXO-338
Study Locations (20)
Other
- CHRU de Montpellier-Hopital St Eloi - Montpellier
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu - Nantes
- Institut Curie - Paris
- Centre hospitalier universitaire de Haut Leveque - Pessac
- IRCCS - AOU di Bologna - Bologna
California
- City of Hope National Medical Center - Duarte
- University of California San Francisco, Medical Center at Paranassus - San Francisco
Florida
- Mayo Clinic in Florida - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
Arizona
- The University of Arizona Cancer Center - Tucson
Georgia
- Emory University - Atlanta
Indiana
- Indiana Blood & Marrow Transplantation (IBMT) - Indianapolis
Kansas
- University of Kansas Medical Center - Westwood
Massachusetts
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT05024045 still lists
NCT05024045 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower).
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Pirtobrutinib is the first listed.
NCT05024045 names 20 study sites across 14 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05024045 about?
NCT05024045 is a clinical study titled "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers". The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
What is the current status of trial NCT05024045?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 316 participants. The study started on 2021-09-30. Estimated completion is 2026-06.
What conditions does trial NCT05024045 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell.
What interventions are being tested in trial NCT05024045?
The interventions under investigation include: Pirtobrutinib (DRUG), LOXO-338 (DRUG).
Who is sponsoring clinical trial NCT05024045?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05024045 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05024045's enrollment target sits among peer trials
316 70th of 438 higher than 369 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI